Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

ClinicalTrials.gov ID: NCT06807268

Public ClinicalTrials.gov record NCT06807268. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 10, 2026, 8:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 16-WEEK, MULTICENTER, INTERVENTIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ABROCITINIB IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to \<12 years of age who have moderate-to-severe eczema. Research study participants who meet the study criteria will be assigned by chance (like the flip of a coin) to receive either abrocitinib test medicine or placebo (pretend medicine that looks just like the test medicine) for 16 weeks. The study will last for about 24 weeks in total.

Study identification

NCT ID
NCT06807268
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
150 participants

Conditions and interventions

Conditions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
6 Years to 11 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 23, 2025
Primary completion
May 1, 2027
Completion
May 1, 2027
Last update posted
Sep 3, 2026

2025 – 2027

United States locations

U.S. sites
13
U.S. states
9
U.S. cities
10
Facility City State ZIP Site status
Cahaba Dermatology & Skin Health Center, LLC Birmingham Alabama 35244 Recruiting
Arkansas Research Trials North Little Rock Arkansas 72117 Recruiting
Investigational Drug Service - Rady Childrens Hospital-San Diego San Diego California 92123 Recruiting
University of California, San Diego/Rady Children's Hospital-San Diego; Pediatric & Adolescent Derm San Diego California 92123 Recruiting
Solutions Through Advanced Research Jacksonville Florida 32256 Recruiting
Ada West Research Meridian Idaho 83646 Recruiting
Dawes Fretzin Clinical Research Group, LLC Indianapolis Indiana 46250 Recruiting
Saint Louis University - Department of Dermatology St Louis Missouri 63104 Recruiting
Medical University of South Carolina - Department of Dermatology Charleston South Carolina 29425 Recruiting
Medical University of South Carolina - South Carolina Translational Research Nexus Clinic Charleston South Carolina 29425 Recruiting
Medical University of South Carolina - Walton Research Building Charleston South Carolina 29425 Recruiting
Tribe Clinical Research, LLC Greenville South Carolina 29607 Recruiting
Texas Dermatology and Laser Specialists San Antonio Texas 78235 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06807268, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 3, 2026 · Synced Sep 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06807268 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →